TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus

Mandvi Bharadwaj, Duangtawan Thammanichanond, Campbell Kynoch Aitken, Sarah Moneer, Heidi E. Drummer, Samantha Lilly Tracy, Rhonda Holdsworth, Scott Bowden, David Jackson, Margaret Hellard, Joseph Torresi, James McCluskey

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

To analyse the immune correlates in a setting of recurrent exposure to hepatitis C virus (HCV), we studied TCD8 responses in injecting drug users (IDUs) with different disease outcomes. Ex vivo HCV-specific T CD8 responses assessed by interferon-γ (IFNγ) enzyme-linked immunospot (ELISPOT) were comparable in human lymphocyte antigen (HLA)-matched IDUs with spontaneous HCV clearance or persistent infection. A detailed characterization of these TCD8 cells in age and HLA-matched IDUs demonstrated that HCV clearance and protection from reinfection correlated with HCV-specific TCD8 cells that could proliferate in vitro, possessed cytotoxic potential and produced IFNγ and tumour-necrosis factor-α, rather than with the circulating frequency of responding T CD8 cells determined ex vivo. While validating the importance of multifunctional TCD8 in mediating protection in IDUs with recurrent exposure to HCV our findings highlight that the magnitude and/or breadth of HCV-specific TCD8 determined in ex vivo ELISPOT may not be the sole determinant of protection especially in a setting of recurrent exposure.

Original languageEnglish
Pages (from-to)464-472
Number of pages9
JournalImmunology and Cell Biology
Volume87
Issue number6
DOIs
Publication statusPublished - Aug 2009
Externally publishedYes

Keywords

  • Hepatitis C virus
  • Injecting drug users
  • T-cell response

Cite this